The results of recent clinical trials have shown their safety and almost non-existing risk of autoimmune reactivity when being tested for the treatment of lung cancers and esophageal cancers; activating IMP3 specific T-cell immune response in patients with the HLA-A 24-positive carcinoma of the esophagus and lung.[33,36,38]. Here, HLA-A is linked to carcinoma of esophagus.